Medical affairs evolution and the future for MSLs
Updated: Jul 4, 2022
Season 02: episode 19
In this week’s episode, the GOLD team is joined by Luca Dezzani, Vice President, Oncology Medical Affairs, Johnson & Johnson. After first meeting Luca when he contributed to a GOLD article about the transition from medicine to medical affairs in 2021, we invited him to join us on the airwaves to delve further into his experience within the function.
He discusses how the medical affairs function has evolved over the last 10 years, the future of the Medical Science Liaison (MSL), his views on the metaverse and the increasing prevalence and power of cross-industry partnership.
The team also covers a recent exhibition created by CSL Behring in collaboration with portrait photographer Rankin that aims to showcase the stories of those living with haemophilia from the twentieth century to modern times.
A little more on GOLD’s guest…
Luca Dezzani is a former physician with extensive healthcare experience in clinical practice and in the pharmaceutical industry. He practised as a physician in haematology and internal medicine before joining Novartis Oncology in 2012, and, since then, he has held a range of medical roles at Eisai and AstraZeneca, including Franchise Head of US Oncology for Medical Affairs. More recently, he joined Johnson & Johnson in 2021 as their Vice President for Oncology Medical Affairs. He has a strong expertise in oncology clinical development and medical affairs, and he is passionate about utilising new technologies to improve outcomes in healthcare.
If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
Click here to subscribe to the weekly newsletter for more insights from GOLD.